UNSPSC 51182438: Teriparatide acetate

This classification denotes a recombinant parathyroid hormone with the molecular formula C181H291N55O51S2.C2H4O2.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9959P4V12N. European Medicines Agency schedules teriparatide acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04726MIG. The term teriparatide acetate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule teriparatide acetate under HS 29371900 and SITC 54154.

As of Q4 2014, TERIPARATIDE ACETATE remains US FDA's Preferred Term for this commodity. Teriparatide acetate bears US NLM identifiers UMLS ID C1170286 and NCI Concept Code C66588. SMILES: CC(=O)O.O.

UNSPSC 51182438 Teriparatide acetate is a Commodity code capturing pharmaceutical products supplied through state and local cooperative purchasing vehicles and direct government procurement. State and local governments buy teriparatide acetate and related branded or generic pharmaceuticals as part of broader multi-source drug supply agreements administered through cooperative purchasing alliances, health departments, and institutional procurement offices serving state agencies, counties, municipalities, and public health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, recently solicited suppliers for generic multi-source pharmaceuticals and over-the-counter products available to participating state and local government facilities across multiple states. Vendors supply through authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with pricing structured as fixed price, net price formats, or WAC-minus arrangements. Compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA) is mandatory, and vendors must maintain commercial general liability insurance of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. Contract terms typically run two years for new suppliers with optional extensions, and purchases are subject to a 3 percent administrative fee with performance penalties of $200 to $1,500 per violation.

The MMCAP RFP posted January 20, 2026, with a response deadline of March 26, 2026, represents the primary recent opportunity under this code. The cooperative purchasing model indicates activity across Minnesota and participating states including Oregon, though specific geographic concentration and repeat buyers within the recent-opportunities block are not detailed. Evaluation emphasizes price competitiveness (75 percent weight), with smaller allocations for fixed pricing, administrative compliance, EDI capability, and fee structure agreement. Award structure allows sole, dual, or multi-awards based on therapeutic considerations and patient safety, with contract effectiveness targeted for July 1, 2026, contingent on product availability in the marketplace by May 15, 2026.